Sorry, your browser doesn't support embedded videos.

Issue 164 • July 2026

Made in the USA

The US is positioning itself as the next growth market for pharmaceutical manufacturing, backed by policy, capital and innovation.

Briefing

Trump proposes 100% generics tariff rate in 2028

Feature

NAMs move into the mainstream

Feature

US presses on with pharma security agenda

Interview

AI governance a fundamental pillar in the hospital pharmacy

In association with

07/27/2026 09:02:45
  • Home | Made in the USA
  • Editor's letter
  • Contents
  • Endress+Hauser
  • LAST Technology
  • Randox Company Insight
  • Randox
  • Compounding Solutions Company Insight
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Protomatic
  • Trilogy Writing & Consulting
  • CPHI Media Partnership
  • In Depth
  • The US manufacturing comeback: Why resilience is becoming the new supply chain strategy
  • NAMs move into the mainstream - and US manufacturing capacity is racing to catch up
  • Not made in China: US presses on with pharma security agenda
  • AI tools bridging preclinical to FIH are now a necessity, not a nice to have
  • Data-first: AI governance a fundamental pillar in the hospital pharmacy
  • ASCO26: AI innovations show promise in reducing the oncology RWD burden
  • The celebrity prescription
  • AI in oncology: trials, tribulations and future opportunities
  • Datwyler Company Insight
  • Datwyler
  • Molnar-Institute Company Insight
  • Molnar-Institute
  • Events
  • Next issue
07/27/2026 00:00:00